Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol

被引：0
|
作者：
Vetterlein, O. [1 ]
Kopotsha, T. M. [1 ]
Nesbitt, A. M. [1 ]
Brown, D. T. [1 ]
Stephens, S. [1 ]
机构：
[1] Celltech Antibody Ctr Excellence, Antibody Biol Div, Slough, Berks, England
来源：
GUT | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
356
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 50 条
  • [21] Certolizumab Pegol for Active Crohn's Disease
    Blackmore, Laura J.
    Harris, Adam W.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (03) : 327 - 327
  • [22] Certolizumab pegol for the treatment of Crohn's disease
    Baker, Danial E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (06) : 683 - 691
  • [23] Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
    Wade, Janet R.
    Parker, Gerry
    Kosutic, Gordana
    Feagen, Brian G.
    Sandborn, William J.
    Laveille, Christian
    Oliver, Ruth
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 866 - 874
  • [24] Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease
    Niels Vande Casteele
    Diane R. Mould
    Jason Coarse
    Iram Hasan
    Ann Gils
    Brian Feagan
    William J. Sandborn
    Clinical Pharmacokinetics, 2017, 56 : 1513 - 1523
  • [25] Clinical Response to Infliximab after Secondary Failure with Adalimumab or Certolizumab Pegol in Crohn's Disease
    Trivella, Juan
    Yarur, Andres
    Moroney, James
    Deshpande, Amar
    Abreu, Maria
    Sussman, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S560 - S561
  • [26] Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease
    Feagan, Brian
    Tan, Seng
    Malone, Daniel
    Hinojosa, Joaquin
    Brown, Martin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S392 - S392
  • [27] Efficacy of certolizumab pegol therapy in patients with Crohn's disease.
    Shafran, I
    Al-Maani, S.
    Burgunder, P.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S62 - S62
  • [28] Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease
    Vande Casteele, Niels
    Mould, Diane R.
    Coarse, Jason
    Hasan, Iram
    Gils, Ann
    Feagan, Brian
    Sandborn, William J.
    CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1513 - 1523
  • [29] Estimation of induction and maintenance costs of Infliximab, Adalimumab and Certolizumab Pegol in managing Crohn's Disease
    Feagan, B.
    Tan, S.
    Malone, D.
    Hinojosa, J.
    Brown, M.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S33 - S33
  • [30] Efficacy of Certolizumab Pegol is Not Affected by Baseline Anti-infliximab Antibody Status in Patients with Crohn's Disease with Secondary Infliximab Failure
    Sandborn, William
    Vermeire, Severine
    D'Haens, Geert
    Colombel, Jean-Frederick
    Fedorak, Richard
    Spehlmann, Martina
    Wolf, Douglas
    Mitchev, Krassimir
    Jamoul, Corinne
    Abreu, Maria
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S452 - S452
12345